Focused On-demand Library for Myosin-binding protein C, cardiac-type

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We use our state-of-the-art dedicated workflow for designing focused libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.







Alternative names:

C-protein, cardiac muscle isoform

Alternative UPACC:

Q14896; A5PL00; Q16410; Q6R2F7; Q9UE27; Q9UM53


Myosin-binding protein C, cardiac-type, also known as C-protein, cardiac muscle isoform, plays a pivotal role in heart muscle function. It is a thick filament-associated protein found in the crossbridge region of vertebrate striated muscle A bands, where it interacts with myosin heavy chain (MHC), F-actin, and native thin filaments. This interaction is crucial for modulating the activity of actin-activated myosin ATPase, suggesting a significant role in muscle contraction or structural integrity.

Therapeutic significance:

The protein is implicated in several hereditary heart disorders, including familial hypertrophic cardiomyopathy 4, dilated cardiomyopathy 1MM, and left ventricular non-compaction 10. These conditions highlight the protein's critical role in cardiac health, underscoring the importance of understanding its function for developing targeted therapies to treat or manage these cardiomyopathies effectively.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.